Three conditions bring people to this class off-label. They sit at very different evidence levels — PCOS has randomised human trials behind it, the other two have mechanism and inference. Each carries an interaction the general framing misses.
No approval, no trial
Tirzepatide is approved for obesity and type 2 diabetes. Use in PCOS, hypothyroidism or fibromyalgia is off-label unless an approved indication is independently met — though unlike almost everything else in this library, the PCOS case rests on human trial evidence rather than inference.
The fertility and contraception item below is the single most important thing on this page for anyone with PCOS.
Theorized — the randomised evidence belongs elsewhere in the class
Smoking cessation — class interest, no trial for this agent
Pathophysiology
Nicotine dependence is maintained by mesolimbic dopamine signalling. Quitting also produces an average weight gain of several kilograms, and fear of that gain is a measured barrier to attempting cessation and a measured cause of relapse.
Mechanistic rationale
The randomised evidence in this class is two small trials. Dulaglutide alongside varenicline did not improve abstinence — 63% against 65% — but prevented post-cessation weight gain, −4.6 kg against +0.5 kg. Exenatide alongside a nicotine patch did improve abstinence, 46.3% against 26.8%. Semaglutide has a large observational signal whose own investigators said it does not justify off-label use. Nothing has been tested for this agent, and in every trial the GLP-1 was added to a treatment that already works rather than replacing it.
Community reports
The consistent finding across the randomised literature is the weight, not the quitting. Post-cessation weight gain is real, specific and worth addressing; improved abstinence is not established, and the whole randomised evidence base is roughly 410 participants.
Components carrying the argument: GLP-1 receptor — class inference only
Approved — randomised outcome trials
Type 2 diabetes — the approved indication
Pathophysiology
Type 2 diabetes is insulin resistance plus progressive beta-cell failure, and the incretin response itself is blunted — the GIP arm more so than the GLP-1 arm.
Mechanistic rationale
Tirzepatide is a dual GIP and GLP-1 receptor agonist, and the SURPASS programme produced the largest HbA1c reductions of any injectable in the class — in the region of 2.0 to 2.4 percentage points, with a high proportion of participants reaching HbA1c below 5.7%, a threshold that is not diabetic at all. SURPASS-2 beat semaglutide 1 mg head-to-head on both HbA1c and weight. The SURPASS-CVOT cardiovascular outcome trial ran against dulaglutide rather than placebo — a harder test than the class originally faced — and demonstrated non-inferiority on three-point MACE rather than superiority, with improvements in HbA1c, weight, renal function and all-cause mortality.
Community reports
Grey-market tirzepatide is widely used by people with diagnosed type 2 diabetes on cost grounds. The specific hazard is the combination with insulin or a sulphonylurea: this agent lowers glucose hard enough that the background regimen usually needs reducing, and nobody is doing that reduction for someone dosing from a research vial.
Components carrying the argument: GIP + GLP-1 dual agonism — additive insulinotropic and satiety effects
Randomised human evidence (class)
PCOS — metabolic and reproductive
Pathophysiology
Insulin resistance drives hyperinsulinaemia, which stimulates ovarian theca cells to overproduce androgens and suppresses SHBG — raising free testosterone, disrupting follicular development and producing anovulation. Weight gain worsens insulin resistance, closing the loop.
Mechanistic rationale
This class breaks the loop at its origin. Reducing hyperinsulinaemia lowers ovarian androgen output and raises SHBG; weight loss independently improves insulin sensitivity. Randomised trials of GLP-1 receptor agonists in PCOS report improved insulin sensitivity, reduced androgens, weight loss and improved menstrual regularity — strongest for liraglutide and exenatide, with semaglutide data emerging.
Community reports
Widely reported weight loss, return of regular cycles, reduced hirsutism and acne over months. The cycle reports describe the syndrome’s defining feature rather than a peripheral symptom.
Components carrying the argument: Incretin pathway — independent of the ovary itself
Labelled — act on this
Fertility returns — often unexpectedly
Pathophysiology
Anovulation is a defining feature of PCOS, and many people with it have assumed for years that conception is difficult. Restoring insulin sensitivity and losing 5%—10% of body weight restores ovulation in a substantial proportion.
Mechanistic rationale
Ovulation returning means fertility returning. This class is contraindicated in pregnancy and labels require discontinuation beforehand — two months for semaglutide, one month for tirzepatide. Tirzepatide is additionally labelled as reducing oral contraceptive effectiveness, with backup or non-oral contraception advised for four weeks after starting and after each dose increase, because delayed gastric emptying alters absorption.
Community reports
Unplanned pregnancies on this class in PCOS populations are reported often enough to have acquired an informal nickname. The mechanism is entirely predictable and the risk entirely manageable — if anyone mentions it.
Components carrying the argument: Class-wide; the oral contraceptive interaction is tirzepatide-specific
Off-label — mechanism independent of thyroid
Hypothyroidism
Pathophysiology
Low thyroid hormone lowers basal metabolic rate and promotes fluid retention. The weight gain directly attributable to hypothyroidism is modest — a few kilograms, much of it water — and largely resolves with adequate replacement.
Mechanistic rationale
The drug acts independently of thyroid status. But sequencing matters: if TSH is not in range, correcting replacement is the first intervention and it is free. The specific hazard is that delayed gastric emptying alters levothyroxine absorption — a narrow-therapeutic-index drug that is fasting-dependent and absorption-sensitive. Direction of change is not reliably predictable.
Community reports
Feeling "off" on this class — fatigue and cold, or palpitations and anxiety — is almost always blamed on the drug. In a replaced person those are also the symptoms of drifting out of range, and only a blood test tells them apart.
Components carrying the argument: Interaction is via gastric emptying
Theorized — weight link better supported than the inflammation one
Fibromyalgia
Pathophysiology
A disorder of central pain processing, with non-restorative sleep, fatigue and cognitive symptoms. Obesity is genuinely associated with worse fibromyalgia symptoms, and weight loss has been reported to improve them.
Mechanistic rationale
The mechanical-load and weight argument is reasonable and has observational support. The inflammation argument is weaker than it sounds: fibromyalgia is not an inflammatory disease — CRP is typically normal or only minimally raised — so "lowering the inflammatory baseline" is addressing something that is not clearly elevated to begin with.
Community reports
Reported reductions in pain and improved mobility alongside weight loss. Difficult to separate from the effect of weight loss by any means, which is the point rather than a criticism.
Components carrying the argument: Weight and mechanical load, not central pain processing
What actually has evidence for these conditions
PCOS has treatments that work. Metformin is first-line for the metabolic phenotype; combined hormonal contraceptives address hyperandrogenism and cycle regulation; letrozole is first-line for ovulation induction; inositol has reasonable evidence and an excellent safety profile; approved GLP-1 receptor agonists now have randomised evidence in this population. Weight loss of 5–10% alone restores ovulation in a meaningful proportion.
Levothyroxine is inexpensive, once daily, titrated against a reliable blood test, and restores euthyroid status in most people. Nothing here treats the thyroid. The unglamorous first move in someone still gaining weight is confirming replacement is adequate and correctly taken — fasting, away from calcium, iron, coffee and proton pump inhibitors.
Fibromyalgia has approved pharmacotherapy — pregabalin, duloxetine and milnacipran — and the intervention with the strongest evidence of any kind is graded exercise combined with cognitive behavioural therapy. Sleep is also worth taking seriously: non-restorative sleep is close to universal in fibromyalgia and obstructive sleep apnoea is under-diagnosed in this population.
Note what duloxetine and milnacipran are: serotonin–noradrenaline reuptake inhibitors. The treatments that work in fibromyalgia act centrally, on pain processing. That is the yardstick any peptide rationale should be measured against.
On the boxed warning: the contraindication covers medullary thyroid carcinoma and MEN2, from rodent C-cell findings. That is a specific, uncommon cancer of the parafollicular cells — not Hashimoto thyroiditis, autoimmune thyroid disease, thyroid nodules or goitre, all of which are common and cause avoidable alarm here.
A practical note for fibromyalgia: irritable bowel syndrome is highly comorbid with fibromyalgia, and this class produces substantial gastrointestinal adverse effects. That combination is worth anticipating rather than discovering.
